Chronic Musculoskeletal Pain

Chronic musculoskeletal pain (CMP) refers to persistent pain affecting the muscles, bones, ligaments, tendons, and nerves, typically lasting for more than three to six months. It is a complex and debilitating condition that can significantly impact an individual’s quality of life and daily functioning. Chronic widespread pain (CWP), a common form of CMP, affects approximately 10% of the general population and is observed to increase in prevalence with age, affecting women more frequently than men^[1]. The economic burden of chronic musculoskeletal pain is substantial, accounting for a significant portion of healthcare costs annually^[1].

The biological basis of CMP is multifaceted, involving a complex interplay of genetic, environmental, and psychological factors. Research indicates a significant genetic component, with the heritability of chronic widespread pain estimated to be between 48% and 52%^[1]. Studies have identified common genetic variants associated with CMP, such as a variant on chromosome 5p15.2 (rs13361160 ) linked to joint-specific CWP. This variant is located near the CCT5 and FAM173Bgenes, both of which have shown increased RNA expression in the lumbar spinal cord of mice with inflammatory pain, suggesting their role in pain regulation^[1]. Furthermore, mutations in CCT5 have been associated with hereditary sensory neuropathy. Other genes, including COMT, GCH1, and OPRM1, also contain single nucleotide polymorphisms (SNPs) that have been linked to various pain phenotypes, influencing pain perception and intensity^[1]. Beyond genetics, CMP involves alterations in the nervous system, including central and peripheral sensitization, inflammation, and neurochemical imbalances.

Clinically, chronic musculoskeletal pain presents significant challenges in diagnosis and management due to its subjective nature and diverse manifestations. It is a prevalent condition seen in rheumatology clinics and is often associated with other symptoms such as fatigue, psychological distress, and somatic complaints^[1]. The social importance of CMP is immense, as it represents a major public health problem that leads to substantial impairment, reduced productivity, and a diminished quality of life for millions worldwide. Effective management often requires a multidisciplinary approach, combining pharmacological treatments, physical therapy, and psychological interventions to address the complex physical and emotional dimensions of the condition.

Limitations

Several factors inherent in the study design, genetic methodologies, and the complex nature of chronic musculoskeletal pain itself warrant careful consideration when interpreting the findings. These limitations highlight areas for future research and inform the generalizability and robustness of the reported associations.

Study Design and Statistical Power

Genetic association studies, particularly genome-wide association studies (GWAS), require substantial sample sizes to reliably detect genetic variants that contribute to complex traits. The relatively small sample size for a GWAS in some studies can lead to modest statistical power, especially when attempting to identify variants with small effect sizes ^[2]. This limitation means that even for large meta-analyses, there may be insufficient power to detect all relevant genetic variants, potentially resulting in a lack of reproducibility for some findings. Furthermore, retrospective genotyping and the absence of a power analysis based on prior GWAS data for analgesic drug efficacy mean that results should be considered preliminary, necessitating larger-scale replication studies with diverse populations for confirmation.

Phenotypic Heterogeneity and Measurement Challenges

Chronic pain is a highly complex trait characterized by diverse etiologies and manifestations, leading to significant phenotypic heterogeneity. The inclusion of various pain phenotypes, such as non-joint pain within a chronic widespread pain (CWP) cohort, can introduce variability that may obscure specific genetic associations. While some studies opt to analyze all CWP cases together based on a hypothesis of a common central pain pathway, this approach may limit the ability to identify genetic loci specific to particular pain subgroups, such as individuals with inflammatory conditions like rheumatoid arthritis. Dissecting the phenotype of pain into more granular or quantitative subgroups could potentially increase the power to detect genetic associations.

Generalizability and Genetic Coverage

The findings from genetic association studies are frequently limited to the specific populations studied, and cannot always be generalized to other ethnic groups. For instance, results derived solely from a European American population may not be applicable to other ethnic populations due as pain responses, analgesic efficacy, and genetic variations are known to differ significantly across diverse ancestries^[3]. Beyond population specificity, current genotyping platforms themselves present a limitation, as they typically capture only about two-thirds of all known common genetic variations across the human genome ^[2]. This incomplete genetic coverage can contribute to missing heritability and potentially increase the risk of false discoveries, underscoring the need for more comprehensive genomic sequencing and broader population representation.

Remaining Knowledge Gaps and Mechanistic Insights

Genetic association studies are primarily designed to identify statistical relationships between genetic variants and phenotypes, rather than to elucidate underlying biological mechanisms. Consequently, even when significant associations are identified, extensive additional work is required to characterize the functional roles of these genetic loci and the pathways through which they influence chronic pain. When candidate genetic loci lack annotation, this mechanistic understanding becomes even more challenging, necessitating further research in both animal models and human studies. The fact that individual genetic loci often explain only a small portion of individual differences for even highly heritable traits, such as height, suggests that complex interactions involving environmental factors, gene-environment confounders, and other unidentified genetic or epigenetic influences likely contribute significantly to the remaining knowledge gaps in chronic musculoskeletal pain.

Variants

Genetic variations play a crucial role in an individual’s susceptibility to chronic musculoskeletal pain by influencing processes such as tissue development, inflammation, and cellular signaling. The Growth Differentiation Factor 5 (GDF5) gene, for instance, is vital for the formation and repair of bone, cartilage, and joints. The variant rs143384 in GDF5 is located in a regulatory region and is associated with reduced GDF5expression, which can lead to impaired cartilage development and increased risk of osteoarthritis, a common cause of chronic joint pain. Similarly, variants within theCOL27A1 gene, such as rs4978570 , and the closely located rs1077140 and rs1017360 which are found near KIF12 and COL27A1, are significant as COL27A1encodes a collagen protein essential for the structural integrity of connective tissues. Alterations in these variants can affect collagen synthesis or structure, potentially leading to weaker joints, tendons, and ligaments, thus contributing to chronic pain and conditions like tendinopathy or degenerative disc disease. Another extracellular matrix component,ECM1, encoded by the gene of the same name, is involved in tissue integrity and repair; its variant rs3737240 may influence these processes, impacting the resilience of musculoskeletal tissues to injury and inflammation.

Cellular transport and metabolic pathways also contribute significantly to musculoskeletal health and pain. TheSLC39A8 gene encodes a zinc transporter protein (ZIP8), and the non-synonymous variant rs13107325 alters its function, potentially impairing zinc uptake. Zinc is critical for immune function, enzyme activity, and antioxidant defense, so dysregulation can exacerbate inflammation and oxidative stress, key drivers of chronic pain in joints and muscles. Likewise,SLC44A2 (also known as CTL2) is responsible for choline transport, a molecule essential for neuronal function and cell membrane integrity. The variant rs62129987 in SLC44A2could influence choline availability, thereby affecting neurotransmission or cellular health in pain-sensing pathways and musculoskeletal tissues.

Other variants influence complex cellular processes, including protein regulation, neuronal signaling, and oxidative stress responses. The region encompassing AMIGO3, RNF123, and GMPPB contains the variant rs7628207 . AMIGO3plays a role in neuronal development and axon guidance, potentially linking this variant to pain signaling or neuropathic pain components.RNF123 and WWP2 (with variant rs4985445 ) are E3 ubiquitin ligases, crucial for tagging proteins for degradation, a process vital for regulating inflammatory responses and cellular stress. Dysregulation here could lead to aberrant protein accumulation or altered signaling, contributing to chronic inflammation and pain. Furthermore,GPX7, an antioxidant enzyme, protects cells from oxidative damage, a major factor in inflammatory musculoskeletal conditions; its variant rs111368900 , which is located near SHISAL2A, could impair antioxidant defenses. Finally, FAF2 (with variant rs548227718 ) is involved in endoplasmic reticulum-associated degradation and lipid metabolism, pathways increasingly recognized for their roles in cellular stress and inflammation, suggesting potential links to the pathogenesis of chronic musculoskeletal pain.

Key Variants

RS ID	Gene	Related Traits
rs143384	GDF5	body height osteoarthritis, knee infant body height hip circumference BMI-adjusted hip circumference
rs7628207	AMIGO3, RNF123, GMPPB	multisite chronic pain chronic musculoskeletal pain
rs4978570	COL27A1	chronic musculoskeletal pain
rs1077140 rs1017360	KIF12 - COL27A1	chronic musculoskeletal pain
rs13107325	SLC39A8	body mass index diastolic blood pressure systolic blood pressure high density lipoprotein cholesterol measurement mean arterial pressure
rs548227718	FAF2	chronic musculoskeletal pain
rs62129987	SLC44A2	chronic musculoskeletal pain
rs111368900	GPX7 - SHISAL2A	chronic musculoskeletal pain
rs3737240	ECM1	protein measurement blood protein amount extracellular matrix protein 1 amount chronic musculoskeletal pain Hip pain
rs4985445	WWP2	appendicular lean mass health trait body height chronic musculoskeletal pain size

Classification, Definition, and Terminology

Chronic musculoskeletal pain (CWP) is a complex condition characterized by widespread pain across specific body regions.

• Definition of Chronic Musculoskeletal Pain (CWP)CWP is defined as the presence of pain in the left side of the body, the right side of the body, above the waist, below the waist, and in the axial skeleton^[4]. This definition aligns with the Fibromyalgia Criteria established by the American College of Rheumatology ^[4].

• Related Concepts and Classifications

  • Musculoskeletal pain is a broad category encompassing conditions commonly seen in rheumatology clinics ^[5]. CWP falls under this umbrella.
  • The Fibromyalgia Criteria of the American College of Rheumatologyprovides a standardized framework for classifying widespread pain, which is adopted in the definition of CWP^[4].
  • A central pain stateis hypothesized to be a fundamental mechanism in the development of CWP. This involves the sensitization of second-order spinal neurons, suggesting an altered processing of pain signals within the central nervous system.

• Clinical Context CWP is a prevalent condition that frequently brings individuals to rheumatology clinics ^[5]. It carries a significant healthcare burden, accounting for 6.2% of the total healthcare costs in The Netherlands annually ^[5]. While CWP can be initiated by an initial local pain stimulus—such as an acute injury, athletic injuries, low back pain, or localized pain resulting from osteoarthritis (OA) or rheumatoid arthritis (RA)—only a subset of affected individuals progress to develop CWP^[6]. Researchers suggest that various discrete stimuli might trigger CWP through a common underlying pathway, leading to the generation of a central pain state.

Chronic musculoskeletal pain (CWP) is characterized by pain experienced in the left side of the body, the right side of the body, above the waist, below the waist, and in the axial skeleton. It is considered a complex trait, often involving various underlying pathways that contribute to its diverse presentation among individuals.

Typical Presentations

Individuals with chronic musculoskeletal pain frequently exhibitcentral sensitization, a state where persistent pain is generated through the sensitization of second-order spinal neurons^[7]. This mechanism contributes to pain hypersensitivity ^[7]. For instance, nervous system hyperalgesia, which is an increased sensitivity to painful stimuli, has been linked to affecting pain levels, disability, and overall quality of life in patients with conditions such as knee osteoarthritis^[8].

Chronic musculoskeletal pain can manifest in different forms. Rheumatoid arthritis (RA), for example, is a chronic systemic inflammatory disorder that primarily impacts the synovial joints^[9].

Measurement Approaches

The clinical definition of pain has historically relied on subjective assessments, including questionnaires and pain homunculus. However, ongoing pain research emphasizes the importance of incorporating more quantitative and objective methods to measure pain in response to painful stimuli, moving beyond solely reported pain.

Approaches used or considered for dissecting the pain phenotype into quantitative sub-phenotypes include:

• Quantitative Sensory Testing (QST):This method involves assessing an individual’s pain sensitivity and their thresholds for various stimuli, such as temperature or pressure^[10].
• Functional Magnetic Resonance Imaging (fMRI):This neuroimaging technique allows for the examination of brain activation patterns associated with pain^[11]. Real-time fMRI offers the potential for observing and even learning to control brain activation related to pain^[11].

Variability

Chronic musculoskeletal pain shows considerable variability among individuals, influenced by both genetic predispositions and environmental factors.

Phenotypic Heterogeneity:Pain is recognized as a highly complex trait, with diverse underlying causes that lead to varied presentations among different individuals. This heterogeneity suggests the existence of distinct subgroups, such as individuals with rheumatoid arthritis, who may experience pain differently^[9].

Sex Differences:The prevalence of chronic widespread pain is approximately two times higher in women compared to men^[12]. Research also indicates that women generally have a lower tolerance for thermal and pressure pain than men^[12].

Genetic Influences:Genetic factors play a significant role in influencing an individual’s susceptibility to chronic widespread pain^[13]. For example, genetic variations within the hypothalamic-pituitary-adrenal stress axis have been shown to influence susceptibility to musculoskeletal pain^[14]. Similarly, genetic variation in the beta2-adrenergic receptor has been associated with chronic pain^[15].

Environmental Factors:External elements, such as trauma and work-related incidents, are identified as risk factors that can contribute to the development of various pain syndromes^[16].

Causes

Chronic musculoskeletal pain is a complex condition influenced by both genetic predispositions and environmental factors. Research indicates that various genetic variations can modulate an individual’s susceptibility to pain, while processes like inflammation and central nervous system changes contribute to its development and persistence.

Genetic Factors

Several genes and genetic variations have been implicated in the development and modulation of chronic musculoskeletal pain:

• Dopamine Receptor D3 (DRD3): A polymorphism in the DRD3 gene, specifically the Ser9Gly variant, has been linked to individual differences in thermal pain perception and its modulation^[17].
• Hypothalamic-Pituitary-Adrenal (HPA) Axis: Genetic variations within the HPA stress axis are recognized to influence an individual’s susceptibility to musculoskeletal pain^[14].
• Catechol-O-methyltransferase (COMT): The COMT gene, involved in catecholamine metabolism, exhibits genetic polymorphisms that correlate with individual variations in S-COMT activity ^[18]. The COMT val158met genotype has been shown to affect mu-opioid neurotransmitter responses to pain stressors^[19]. While some studies found no significant association between COMT and chronic pain susceptibility^[15], other research identified two COMT single nucleotide polymorphisms (SNPs), rs2020917 and rs5993883 , associated with pain. The minor allele ofrs2020917 demonstrated a protective effect, while the minor allele of rs5993883 showed an adverse effect, leading to increased pain^[20]. These COMT SNPs are in weak linkage disequilibrium with the well-known amino acid changing variant rs4860 ^[20].
• Beta2-Adrenergic Receptor: Genetic variation in the beta2-adrenergic receptor gene has been found to predispose individuals to chronic pain^[15].
• CCT5 and FAM173B: A common genetic variant located on chromosome 5p15.2, near the CCT5 and FAM173B genes, is associated with joint-specific chronic widespread pain (CWP)^[20]. Studies in mouse models of inflammatory pain showed higher RNA expression of Cct5 and Fam173b in the lumbar spinal cord, suggesting their role in pain regulation^[20]. A mutation in CCT5 has also been linked to hereditary sensory neuropathy, a syndrome characterized by a sensory deficit ^[20].
• Mu-Opioid Receptor (OPRM1): A genetic variant (SNP rs599548 ) in the OPRM1 gene, which encodes the mu-opioid receptor, is associated with pain, with individuals carrying the minor allele experiencing more pain^[20].
• Rheumatoid Arthritis (RA) Related Genes: While chronic musculoskeletal pain can be a feature of conditions like rheumatoid arthritis (RA), and RA has known genetic associations (e.g., the HLA locus)^[21], these specific RA-related genetic variants were not found to be primary drivers in studies focusing on general chronic widespread pain^[20]. The prevalence of RA is relatively low ^[9].

Environmental Factors

Environmental and physiological factors play a significant role in the etiology of chronic musculoskeletal pain:

• Inflammatory Processes: Inflammatory pain, as observed in mouse models, can lead to changes in gene expression (e.g., Cct5 and Fam173b) in the spinal cord, indicating its role in pain mechanisms^[20].
• Central Sensitization: The development of a central pain state, characterized by the sensitization of second-order spinal neurons, is considered a common final pathway for chronic widespread pain. This process generates pain hypersensitivity through central neural plasticity^[7].
• Stress: Variations in the HPA stress axis influence susceptibility, suggesting that stress, as an environmental factor, may interact with genetic predispositions to contribute to musculoskeletal pain^[14].

Chronic musculoskeletal pain is a complex condition influenced by both genetic predispositions and environmental factors. The individual variability observed in pain sensitivity and responses to analgesic medications is understood to arise from a complex interplay of multiple gene polymorphisms and environmental factors^[12].

A fundamental biological mechanism implicated in chronic widespread pain (CWP), a common form of chronic musculoskeletal pain, is central sensitization^[7]. This process involves the sensitization of second-order spinal neurons, which generates a central pain state and contributes to pain hypersensitivity through central neural plasticity^[7].

Genetic variations play a significant role in an individual’s susceptibility to chronic musculoskeletal pain and their perception of pain. Research has investigated polymorphisms in genes associated with neurotransmitter systems and stress responses. For example, theDRD3 Ser9Gly polymorphismhas been linked to thermal pain perception and its modulation in individuals with chronic widespread pain, as well as in healthy controls^[17].

The hypothalamic-pituitary-adrenal (HPA) stress axis, a crucial system governing the body’s response to stress, also features genetic variations that influence susceptibility to musculoskeletal pain^[14].

The enzyme catechol-O-methyltransferase (COMT) is involved in the metabolic breakdown of catecholamines, such as dopamine, norepinephrine, and epinephrine. Genetic polymorphisms in COMT correlate with individual differences in its enzymatic activity ^[18]. Specifically, the COMT val158met genotypehas been shown to affect mu-opioid neurotransmitter responses when an individual experiences a pain stressor^[19]. While some studies suggest that genetic variation in COMT may not predispose individuals to chronic pain, genetic variation in thebeta2-adrenergic receptorhas been associated with a predisposition to chronic pain^[15].

Pathways and Mechanisms

Chronic musculoskeletal pain (CWP) often originates from an initial local pain stimulus, such as an acute injury, athletic injuries, low back pain, or pain associated with conditions like osteoarthritis or rheumatic arthritis^[22]. While many individuals experience such stimuli, only a subset develops CWP. It is hypothesized that various discrete stimuli can converge on a common final pathway, leading to a central pain state through the sensitization of second-order spinal neurons^[7]. This central sensitization results in heightened pain sensitivity and persistence.

Several molecular and physiological mechanisms contribute to the development and maintenance of chronic pain:

• Immune Cell Involvement and Signaling:Microglial and macrophage activity plays a role in determining the duration of peripheral inflammation-induced pain hypersensitivity. This involves signaling pathways in the spinal cord, including CX3CR1, p38, and IL-1 signaling, regulated by the G protein-coupled receptor kinase 2 (GRK2)^[22].
• Nociceptor Regulation:Ephrin-B2, a molecule expressed on nociceptors (pain-sensing neurons), is involved in regulating both inflammatory and neuropathic pain^[23].
• Biochemical Regulators:Molecules such as GTP cyclohydrolase and tetrahydrobiopterin are known to regulate pain sensitivity and its persistence^[24].
• Genetic Influences on Pain Modulation:Genetic variations can significantly impact an individual’s susceptibility to chronic pain and how they perceive and modulate pain^[12].
  • Dopamine Receptor D3 (DRD3):A specific genetic variation, the DRD3 Ser9Gly polymorphism, has been linked to thermal pain perception and modulation in individuals with CWP and in healthy controls^[17].
  • Hypothalamic-Pituitary-Adrenal (HPA) Axis:Genetic variations within the HPA stress axis, which regulates the body’s response to stress, can influence an individual’s susceptibility to musculoskeletal pain^[14].
  • Catechol-O-methyltransferase (COMT): Genetic polymorphisms in the COMT enzyme, which metabolizes neurotransmitters like dopamine, can correlate with individual differences in COMT activity ^[18]. The COMT val158met genotype, for instance, affects how the brain’s mu-opioid system responds to pain stressors^[19]. Variations in COMT have also been found to be significant in conditions like fibromyalgia syndrome, a form of chronic widespread pain^[25]. However, some studies suggest that genetic variation in the beta2-adrenergic receptor, rather than COMT, may predispose individuals to chronic pain^[15].
  • Beta2-Adrenergic Receptor:Genetic variations in the beta2-adrenergic receptor gene have been shown to predispose individuals to chronic pain^[15].

Ethical or Social Considerations

Chronic musculoskeletal pain carries significant social implications, particularly concerning its economic burden on healthcare systems. This condition accounts for a substantial portion of healthcare expenditures, for instance, representing 6.2% of the total healthcare costs in The Netherlands annually^[5]. Such economic impact necessitates careful consideration of resource allocation and public health planning.

Frequently Asked Questions About Chronic Musculoskeletal Pain

These questions address the most important and specific aspects of chronic musculoskeletal pain based on current genetic research.

---

1. Why does my chronic pain feel worse than my friend’s?

Your pain perception can be strongly influenced by your unique genetic makeup. Variations in genes likeCOMT, GCH1, and OPRM1affect how your body processes pain signals, making some individuals more sensitive or less tolerant to discomfort than others. This means two people with similar conditions can experience very different levels of pain intensity.

2. Will my kids definitely inherit my chronic pain issues?

Not necessarily, but there is a significant genetic component. Research indicates that chronic widespread pain is about 48-52% heritable, meaning genetics play a substantial role in susceptibility. While your children might inherit some genetic predispositions, environmental factors and lifestyle choices also heavily influence whether they develop chronic pain.

3. Why are women more likely to suffer from chronic pain like me?

Yes, chronic widespread pain is observed to affect women more frequently than men. This higher prevalence is thought to involve a complex interplay of genetic factors interacting with hormonal differences and other biological pathways unique to women. These interactions can contribute to distinct pain experiences and susceptibility.

4. Does my family history mean I’m stuck with this pain?

No, a family history increases your risk, but it doesn’t mean you’re destined to suffer. While genetics contribute significantly, your lifestyle, environmental factors, and psychological well-being also play crucial roles. A multidisciplinary approach combining physical therapy, pharmacological treatments, and psychological interventions can effectively manage and potentially mitigate your pain.

5. Can stress actually make my body pain feel much worse?

Yes, stress can definitely amplify your pain perception and make chronic pain feel more intense. Chronic musculoskeletal pain involves complex interactions between your genetic predispositions, your nervous system, and psychological factors. Stress can heighten central sensitization, making your brain more reactive to pain signals, even without a change in the physical condition itself.

6. Is there a genetic test to understand my chronic pain better?

While research has identified specific genetic variants associated with chronic pain, such as those near theCCT5 gene or in COMT, routine genetic tests for general chronic musculoskeletal pain are not widely used clinically yet. These tests primarily help researchers understand underlying mechanisms rather than providing individual diagnostic or prognostic information in a practical setting.

7. Does my ethnicity affect my chances of getting chronic pain?

Yes, your ethnic background can influence your pain risk and how you respond to pain. Genetic variations, pain responses, and even the effectiveness of certain pain medications are known to differ across diverse ancestries. Therefore, research findings from one population, like European Americans, may not always be directly applicable to other ethnic groups.

8. Why do some people never seem to get chronic body aches?

Some individuals may have a genetic profile that makes them less susceptible to chronic pain. For example, specific variations in genes likeCOMTcan influence how effectively their body processes pain signals, leading to a higher pain threshold or better natural pain modulation compared to others. This genetic difference can make them less prone to persistent discomfort.

9. Does my age increase my risk for developing chronic pain?

Yes, the prevalence of chronic widespread pain is observed to increase with age. This can be due to a combination of factors, including age-related wear and tear on tissues, accumulated environmental exposures over time, and potential changes in gene expression or neurological function that contribute to increased pain susceptibility.

10. Can exercise help even if my pain is partly genetic?

Absolutely, exercise is a crucial part of managing chronic pain, even if you have a genetic predisposition. Physical therapy and regular activity can help strengthen muscles, improve flexibility, reduce inflammation, and enhance your body’s natural pain-modulating systems. These benefits can significantly improve your quality of life and reduce pain severity.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] van der Paard, M. J. P., et al. “Genome-wide association study identifies a common variant in the CCT5 gene associated with chronic widespread pain.”British Journal of Ophthalmology, 2012.

[2] Pe’er, I., de Bakker, P. I., Maller, J., et al. “Evaluating and improving power in whole-genome association studies using fixed marker sets.” Nat. Genet, vol. 38, no. 6, 2006, pp. 663–667.

[3] Edwards, C., Fillingim, R., Keefe, F. “Race, ethnicity and pain.”Pain, vol. 94, no. 2, 2001, pp. 133–137.

[4] Wolfe, F., Smythe, H. A., Yunus, M. B., et al. “The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee.” Arthritis & Rheumatism, vol. 33, no. 2, 1990, pp. 160–72.

[5] Meerding, W. J., Bonneux, L., Polder, J. J., et al. “Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study.” BMJ, vol. 317, 1998, pp. 111–15.

[6] Leffler, A. S., Kosek, E., Lerndal, T., et al. “Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis.”European Journal of Pain, vol. 6, no. 2, 2002, pp. 161–76.

[7] Latremoliere A, Woolf CJ. “Central sensitization: a generator of pain hypersensitivity by central neural plasticity.”J Pain, vol. 10, 2009, pp. 895–926.

[8] Imamura, M, et al. “Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: a controlled analysis.”Arthrit Rheum-Arthr, vol. 59, 2008, pp. 1424–31.

[9] Silman AJ, Pearson JE. “Epidemiology and genetics of rheumatoid arthritis.”Arthritis Res, vol. 4, no. Suppl 3, 2002, pp. S265–72.

[10] Rolke, R, et al. “Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.”Pain, vol. 123, 2006, pp. 231–41.

[11] deCharms, R. C., et al. “Control over brain activation and pain learned by using real-time functional MRI.”Proc Natl Acad Sci USA, vol. 102, 2005, pp. 18626–31.

[12] Moller, A. T., and T. S. Jensen. “Pain and genes: Genetic contribution to pain variability, chronic pain and analgesic responses.”Eur J Pain Supplements, vol. 4, 2010, pp. 197–201.

[13] Kato, K, et al. “Importance of genetic influences on chronic widespread pain.”Arthritis Rheum, vol. 54, 2006, pp. 1682–6.

[14] Holliday KL, Nicholl BI, Macfarlane GJ, et al. “Genetic variation in the hypothalamic-pituitary-adrenal stress axis influences susceptibility to musculoskeletal pain: results from the EPIFUND study.”Ann Rheum Dis, vol. 69, 2010, pp. 556–60.

[15] Hocking LJ, Smith BH, Jones GT, et al. “Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study.”Pain, vol. 149, 2010, pp. 143–51.

[16] Buskila, D., and R. Mader. “Trauma and work-related pain syndromes: risk factors, clinical picture, insurance and law interventions.”Best Pract Res Cl Rh, vol. 25, 2011, pp. 199–207.

[17] Potvin S, Larouche A, Normand E, et al. “DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls.”J Pain, vol. 10, 2009, pp. 969–75.

[18] Syvanen AC, Tilgmann C, Rinne J, et al. “Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland.” Pharmacogenetics, vol. 7, 1997, pp. 65–71.

[19] Zubieta JK, Heitzeg MM, Smith YR, et al. “COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.”Science, vol. 299, 2003, pp. 1240–3.

[20] Gursoy S, Erdal E, Herken H, et al. “A common genetic variant on chromosome 5p15.2 associated with joint-specific CWP in humans and the role of CCT5 and FAM173B.”

[21] Bax M, van Heemst J, Huizinga TW, et al. “Genetics of rheumatoid arthritis: what have we learned?”Immunogenetics, vol. 63, 2011, pp. 459–66.

[22] Willemen, H. L., et al. “Microglial/macrophage GRK2 determines duration of peripheral IL-1beta-induced hyperalgesia: contribution of spinal cord CX3CR1, p38 and IL-1 signaling.” Pain, vol. 150, 2010, pp. 550–60.

[23] Zhao, J., et al. “Nociceptor-expressed ephrin-B2 regulates inflammatory and neuropathic pain.”Molecular Pain, vol. 6, 2010, p. 77.

[24] Tegeder, I., et al. “GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence.”Nature Medicine, vol. 12, 2006, pp. 1269–73.

[25] Gursoy, S., et al. “Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.” Rheumatology International, vol. 23, 2003, pp. 104–7.